Telix has announced that the first patient has been dosed in an early access program in the Netherlands for its investigational positron emission tomography imaging agent TLX250-CDx in clear cell renal cell carcinoma. …
Telix says the first patient dosed in European early access program for TLX250-CDx
December 6, 2023 Australian Biotech
Latest Video
New Stories
-
An exchange that reveals the truth of a review that has now become a lot like 'Weekend at Bernie's'
June 3, 2026 - - Latest News -
Patient voices take centre stage at the 2026 Patient's Choice Awards
June 3, 2026 - - Latest News -
Officials confirm shift in Budget management of underspends
June 3, 2026 - - Latest News -
Invitation confusion clouds Delphi studies and captures medical device sector
June 3, 2026 - - Latest News -
Omico opens a new chapter in precision oncology research
June 1, 2026 - - Latest News -
Ex-MA executive named the first CEO of Medicinal Cannabis Council Australia
June 1, 2026 - - Latest News -
Oral RAS inhibitor doubles median survival and cuts death risk in metastatic pancreatic cancer
June 1, 2026 - - Latest News